Pharmacokinetics of memantine in rats and mice

PLoS Currents

Volumn , Issue , 2012, Pages

  Beconi, Maria G ^a   Howland, David ^a   Park, Larry ^a   Lyons, Kathryn ^a   Giuliano, Joseph ^a   Dominguez, Celia ^a   Munoz Sanjuan, Ignacio ^a   Pacifici, Robert ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STABILITY; DRUG STRUCTURE; EX VIVO STUDY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PREDICTIVE VALUE; RAT; SINGLE DRUG DOSE; STEADY STATE; ANIMAL CELL; ANIMAL TISSUE; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84867472278     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1291     Document Type: Article

References (16)

1. NDA 21-487. Memantine HCl. Forest laboratories, Inc. 24-September-2003.
2. Winblad B, Poritis N. 1999. Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 14:135-146.
3. Miguel-Hidalgo J, Alvarez H, Cacabelosb R, and Quackc G. 2002. Neuroprotection by memantine against neurodegeneration induced by b-amyloid(1-40). Brain Research. 958:210-221
4. Papadia S, Hardingham GE. 2007. The dichotomy of NMDA receptor signaling. Neuroscientist. 13:572-9. Review.
5. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. 2010. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 65:178 190.
6. Cowan CM, Raymond LA. 2006. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol. 75:25-71. Review.
7. Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. 2007. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J Neurosci. 27:3768-3779.
8. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. 2006. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 21:392-403.
9. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. 2009. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15:1407-13.
10. Subramaniam S, Sixt KM, Barrow R, Snyder SH. 2009. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science. 324:1327-30.
11. Subramaniam S, Snyder SH. 2011. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum). Neuropharmacology. 60:1187-92.
12. Papadia S, Hardingham GE. 2007. The dichotomy of NMDA receptor signaling. Neuroscientist. 13:572-9. Review.
13. Kornhuber J, Kennepohl EM, Bleich S, Wiltfang J, Kraus T, Reulbach U, and Meineke I. 2007. Memantine pharmacotherapy: A naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 46:599-612.
14. Periclou A, Ventura D, Rao N, and Abramowitz W. 2006. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clinical Pharmacology and Therapeutics. 79:134-143.
15. Kornhuber J, Quack G. 1995. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neuroscience Letters 195:137-139.
16. Liu M-Y, Meng S-N, Wu H-Z, Wang S, and Wei M-J. 2008. Pharmacokinetics of single-dose and multiple-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clinical Therapeutics. 30:641-653.